CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Clinical and Laboratory Science

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 28801364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti‐CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma

  2016cited by this paper
• Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

  2015cited by this paper
• Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.

  2015cited by this paper
• Genomic analysis of fibrolamellar hepatocellular carcinoma.

  2015cited by this paper
• Diagnostic and therapeutic management of hepatocellular carcinoma.

  2015cited by this paper
• Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.

  2015cited by this paper
• Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer

  2015cited by this paper
• Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma

  2014cited by this paper
• Endoscopic molecular imaging of human bladder cancer using a CD47 antibody

  2014cited by this paper
• The CD47-SIRPα signalling system: its physiological roles and therapeutic application.

  2014cited by this paper
• Blockade of CD47‐mediated cathepsin S/protease‐activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma

  2014cited by this paper
• Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM

  2014cited by this paper
• HTSeq—a Python framework to work with high-throughput sequencing data

  2014cited by this paper
• On the mechanism of CD47 targeting in cancer

  2012cited by this paper
• The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

  2012cited by this paper
• The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

  2012cited by this paper
• CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction

  2011cited by this paper
• Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

  2011cited by this paper
• Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

  2010cited by this paper
• Differential expression analysis for sequence count data

  2010cited by this paper
• Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation

  2010cited by this paper
• Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

  2010cited by this paper
• TopHat: discovering splice junctions with RNA-Seq

  2009cited by this paper
• Primary liver carcinoma arising in people younger than 30 years.

  2005cited by this paper
• Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma

  2005cited by this paper
• Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte.

  2005cited by this paper
• Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population‐based study

  2004cited by this paper
• The C‐terminal 26‐residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47

  2004cited by this paper
• Fibrolamellar hepatocellular carcinoma in children and adolescents

  2003cited by this paper
• Abstracts reprinted from Journal of Clinical Oncology

  2002cited by this paper
• In vivo expression of alternatively spliced forms of integrin-associated protein (CD47).

  1995cited by this paper
• An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains.

  1992cited by this paper

• Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment

  2024cites this paper
• Calreticulin Expression in Human Carcinomas: A Systematic Review and Meta-Analysis

  2023cites this paper
• Deciphering the role of CD47 in cancer immunotherapy

  2023cites this paper
• CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor

  2021cites this paper
• Clinicopathological significance of CD47 expression in hepatocellular carcinoma

  2020cites this paper
• The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors

  2019cites this paper